DYDun Yang

Dun Yang

*This is an algorithmically generated author record based on publicly available information.

Dun Yang has a total of 62 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Discovery of novel, potent and orally available benzoazipinone derivatives that elicit MKLP2-inhibitory phenotypes

    by Jian Huang, Ting Zhang, Julia Kalashova, Jinhua Li, Chenglu Yang, Linsheng Zhong, Xiaohu Zhou, Qiong Shi, Gang Lv, Jiadai Chenyu, et al.


  • Open Access

    Abstract LB_C10: An orally available small molecule inhibitor for synthetic lethal targeting of MYC expressing tumors

    by Qiong Shi, Ting Zhang, Julia Kalashova, Jinhua Li, Chenglu Yang, Hongmei Li, Xiaohu Zhou, Yan Long, Yidan Xia Abuliezi, Gang Lv, et al.

    The potential for synthetic lethality occurs when the same oncogenic events that promote carcinogenesis, also create vulnerabilities for cancer cells. Targeting cancers with these vulnerabilities, but not resident normal tissues, is the promise of synthetic lethal therapies. The compound LC30 is a potent and orally bioavailable compound that is synthetic lethal with deregulated MYC. No off-target liabilities have been demonstrated by kinome and safety profiling and long-term treatment is well tolerated by rodents and canines. LC30 is active against a wide spectrum of cell line xenografts derived from both liquid and solid cancers, including B and T cell malignancies, lung, colon, gastric, mammary and liver cancer cell lines, with efficacy that correlates with levels of MYC. Experiments aimed at unlocking the key to LC30’s synthetic lethality have revealed that LC30 is active in both resting cells and during cell division, so it is not simply an anti-mitotic compound. In resting cells, LC30 disrupts golgi structure, a phenotype that possibly relates to MYC control of centrosomal gene expression. Anti-angiogenic effects are observed in xenografts and have been confirmed using in vitro assays of endothelial cell migration and tubule formation. We speculate that the golgi phenotype and resulting faulty trafficking of secretory vesicles containing pro-angiogenic factors may underly the vascular phenotype. In dividing cells, LC30 potently deregulates the positioning of the chromosomal passenger protein complex (CPPC), a mitotic complex comprised of a catalytic subunit, Aurora B kinase (AURKB), the scaffolding protein inner centromere protein (INCENP) as well as survivin and borealin. The CPPC is dynamically relocated during mitotic progression so that AURKB activity can be localized to specific locations where activity is required. The phenotypic effects of LC30 treatment are consistent with this compound functioning as an inhibitor of the localization, but not catalytic activity of the CPPC. This includes the induction of multipolar spindles, micronuclei and polyploidy, leading to mitotic arrest and both mitotic and post-mitotic apoptosis. This unique mode-of-action, to disrupt CPPC passage in the mitotic cell, is a key component of the MYC synthetic lethality as cells without MYC overexpression do not develop multipolar spindles, lethal polyploidy and apoptose with treatment. LC30 represents a new class of anticancer compound that is a non-kinase, synthetic lethal inhibitor that unlocks MYC-induced vulnerabilities in cancer cells. Citation Format: Qiong Shi, Ting Zhang, Julia Kalashova, Jinhua Li, Chenglu Yang, Hongmei Li, Xiaohu Zhou, Yan Long, Yidan Xia Abuliezi, Gang Lv, Duo Yu, Shenqiu Zhang, Jing Zhang, Thaddeus D Allen, Hong Liu, Dun Yang. An orally available small molecule inhibitor for synthetic lethal targeting of MYC expressing tumors [abstract]. In: Proceedings of the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics; 2023 Oct 11-15; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2023;22(12 Suppl):Abstract nr LB_C10.

  • Open Access

    MYC amplifies mitotic perturbations elicited by LXY18 to enable synthetic lethality

    by Julia Kalashova, Chenglu Yang, Yan Long, Hongmei Li, Shenqiu Zhang, Ting Zhang, Duo Yu, Xumei Liu, Gang Lv, Namrta Choudhry, et al.

    The MYC oncoprotein represents an intriguing target for cancer treatment, but its therapeutic potential has been hindered by the absence of specific pharmacological inhibitors. In this study, we demonstrate that the phenoxy quinoline compound LXY18 selectively targets and eliminates cells overexpressing MYC, leaving non-transformed cells unharmed. This synthetic lethality arises from an acute induction of multipolarity, resulting in a persistent arrest in early mitosis followed by cell death in mitosis or after mitotic slippage. Distinctively, LXY18’s action contrasts with other antimitotic compounds, as they either fail to induce mitotic arrest or elicit mitotic arrest irrespective of MYC abundance. Furthermore, the MYC abundance in a panel of 98 tumor cell lines correlates with their sensitivity to LXY18. Collectively, our findings uncover LXY18 as an MYC- enabled mitotic blocker and open a new avenue to selectively target MYC-overexpressing tumor cells without affecting normal cells.


  • Orally Bioavailable 4-Phenoxy-quinoline Compound as a Potent Aurora Kinase B Relocation Blocker for Cancer Treatment

    by Jinhua Li, Ting Zhang, Qiong Shi, Gang Lv, Xiaohu Zhou, Namrta Choudhry, Julia Kalashova, Chenglu Yang, Hongmei Li, Yan Long, et al.

    We investigated a novel 4-phenoxy-quinoline-based scaffoldthatmislocalizes the essential mitotic kinase, Aurora kinase B (AURKB).Here, we evaluated the impact of halogen substitutions (F, Cl, Br,and I) on this scaffold with respect to various drug parameters. Br-substituted LXY18 was found to be a potent and orally bioavailable disruptorof cell division, at sub-nanomolar concentrations. LXY18 prevents cytokinesis by blocking AURKB relocalization in mitosisand exhibits broad-spectrum antimitotic activity in vitro. With afavorable pharmacokinetic profile, it shows widespread tissue distributionincluding the blood-brain barrier penetrance and effectiveaccumulation in tumor tissues. More importantly, it markedly suppressestumor growth. The novel mode of action of LXY18 may eliminatesome drawbacks of direct catalytic inhibition of Aurora kinases. Successfuldevelopment of LXY18 as a clinical candidate for cancertreatment could enable a new, less toxic means of antimitotic attackthat avoids drug resistance mechanisms.


  • In-vitro metabolism of LXY18, an orally available, potent blocker of AURKB relocation in mitosis

    by Jinhua Li, Namrta Choudhry, Gang Lv, Naganna Nimishetti, Mallu Chenna Reddy, Hong Liu, Thaddeus D. Allen, Jing Zhang, Dun Yang


  • Open Access

    Characterization of mitotic phenotypes associated with a MYC synthetic lethal compound

    by Qiong Shi, Xuemei Liu, Julia Kalashova, Chenglu Yang, Hongmei Li, Yan Long, Ting Zhang, Shenqiu Zhang, Gang Lv, Jian Huang, et al.

    Therapeutic targeting of MYC directly has proven difficult, but several means to target MYC indirectly using a synthetic lethal drug approach have been proposed. Synthetic lethal approaches for MYC have sought to take advantage of vulnerabilities MYC imposes related to either metabolic reprogramming, apoptotic signaling or the cycling of cancer cells. Here, we describe in detail the cell division phenotypes induced by a MYC synthetic lethal compound, dimethylfasudil (diMF). DiMF is a known ROCK inhibitor, but structurally related ROCK inhibitors are not synthetic lethal with MYC, so the activity of diMF is not related to blockade of this family of kinases. Instead, this compound induced multiple cell cycle-related liabilities. These included the early mitotic arrest of cycling cells followed by mitotic catastrophe-induced death and the induction of polyploidy in cells that do manage to pass through mitosis. As early as prometaphase, we noted diminished staining for BUB1 kinase, which binds to kinetochores and regulates the mitotic spindle checkpoint and chromosome congression. Kinetochore proteins, such as CENP-F, failed to localize at the metaphase plate, confirming a deficit in centromere assembly. This, presumably, contributed to the development of segregation anomalies in diMF-treated cells. In anaphase cells, the protein regulator of cytokinesis 1 (PRC1), failed to be recruited to the midzone, leading to a cascade of defects that included failed recruitment of the chromosomal passenger protein complex, the centralspindlin complex and polo-like-kinase 1 (PLK1). These observations correlate well with the cell death phenotypes induced by diMF, which may serve as a prototype MYC synthetic lethal compound to explore synthetic lethal therapy or as a scaffold upon which to build superior compounds. The phenotypes described here serve as examples of MYC synthetic lethal drug effects that can be used to explore and maximize drug discovery programs.

  • Open Access

    An orally bioavailable 4-phenoxy-quinoline compound as a potent AURKB relocation blocker for cancer treatment

    by Jinhua Li, Ting Zhang, Qiong Shi, Gang Lv, Xiaohu Zhou, Namrta Choudhry, Julia Kalashova, Chenglu Yang, Hongmei Li, Yan Long, et al.

    We investigated a novel 4-phenoxy-quinoline-based scaffold that mislocalizes the essential mitotic kinase, AURKB. Here, we evaluated the impact of halogen substitutions (F, Cl, Br, I) on this scaffold with respect to various drug parameters. Br-substituted LXY18 was found to be a potent and orally bioavailable disruptor of cell division, at sub-nanomolar concentrations. LXY18 prevents cytokinesis by blocking AURKB relocalization in mitosis and exhibits broad-spectrum antimitotic activity in vitro . With a favorable PK profile, it shows widespread tissue distribution including the blood-brain barrier penetrance and effective accumulation in tumor tissues. More importantly, it markedly suppresses tumor growth. The novel mode of action of LXY18 may eliminate some drawbacks of direct catalytic inhibition of AURKs. Successful development of LXY18 as a clinical candidate for cancer treatment could enable a new, less toxic means of antimitotic attack that avoids drug resistance mechanisms.


  • Integrating a phenotypic screening with a structural simplification strategy to identify 4-phenoxy-quinoline derivatives to potently disrupt the mitotic localization of Aurora kinase B

    by Gang Lv, Qiong Shi, Ting Zhang, Jinhua Li, Yan Long, Wenhui Zhang, Namrta Choudhry, Kevin Yang, Hongmei Li, Julia Kalashova, et al.


  • 2-Phenoxy-3, 4′-bipyridine derivatives inhibit AURKB-dependent mitotic processes by disrupting its localization

    by Gang Lv, Qiong Shi, Ting Zhang, Jinhua Li, Julia Kalashova, Yan Long, Yin Sun, Chao Li, Namrta Choudhry, Hongmei Li, et al.


  • Open Access

    The Effect of Circumscribed Exposure to the Pan-Aurora Kinase Inhibitor VX-680 on Proliferating Euploid Cells

    by Xumei Liu, Qiong Shi, Namrta Choudhry, Ting Zhang, Hong Liu, Shenqiu Zhang, Jing Zhang, Dun Yang

    Small molecule inhibitors of aurora kinases are currently being investigated in oncology clinical trials. The long-term effects of these inhibitors on proliferating euploid cells have not been adequately studied. We examined the effect of the reversible pan-aurora kinase inhibitor VX-680 on p53-competent human euploid cells. Circumscribed treatment with VX-680 blocked cytokinesis and arrested cells in G1 or a G1-like status. Approximately 70% of proliferatively arrested cells had 4N DNA content and abnormal nuclei. The remaining 30% of cells possessed 2N DNA content and normal nuclei. The proliferative arrest was not due to the activation of the tumor suppressor Rb and was instead associated with rapid induction of the p53–p21 pathway and p16. The induction was particularly evident in cells with nuclear abnormalities but was independent of activation of the DNA damage response. All of these effects were correlated with the potent inhibition of aurora kinase B. After release from VX-680, the cells with normal nuclei robustly resumed proliferation whereas the cells with abnormal nuclei underwent senescence. Irrespective of their nuclear morphology or DNA content, cells pre-treated with VX-680 failed to grow in soft agar or form tumors in mice. Our findings indicate that an intermittent treatment strategy might minimize the on-target side effects of Aurora Kinase B (AURKB) inhibitory therapies. The strategy allows a significant fraction of dividing normal cells to resume proliferation.